Table 1. Patient demographics, visual acuity, central retinal thickness and complications.
| Age | Sex | Antiplatelet/ anticoagulant | Treatment for systemic hypertension | Symptom onset to treatment (days) | Baseline VA LogMAR (Snellen) | Baseline CRT (μm) | Displacement of subfoveal haemorrhage | Final VA LogMAR (Snellen) | Final CRT (μm) | Complications |
|---|---|---|---|---|---|---|---|---|---|---|
| 80 | F | Aspirin, clopidogrel | Yes | 2 | 1.78 (1/60) | 819 | Yes | 0.18 (6/9) | 222 | None |
| 85 | F | None | Yes | 5 | 2.28 (HM) | Yes | 0.78 (6/36) | 234 | Raised IOP, vitreous haemorrhage | |
| 84 | M | Warfarin | Yes | 3 | 1.78 (1/60) | 588 | Yes | 0.6 (6/24) | 284 | None |
| 73 | M | Aspirin | Yes | 2 | 0.78 (6/36) | 704 | Yes | 0.32 (6/12) | 209 | Vitreous haemorrhage |
| 86 | M | Aspirin | Yes | 4 | 1.3 (3/60) | 366 | Yes | 0.5 (6/18) | 316 | None |
| 78 | F | Rivaroxaban | Yes | 3 | 1.98 (CF) | 695 | Yes | 1.26 (3/60) | 613 | PED Rip |
| 79 | M | Aspirin | Yes | 3 | 1.46 (2/60) | 551 | Yes | 0.68 (6/30) | 214 | None |
| 83 | F | Aspirin | Yes | 2 | 1.98 (CF) | 884 | Yes | 0.68 (6/30) | 358 | None |
| Mean | 3 | 1.67 | 658.1 | 0.63 | 316.6 |